Durhane Wong-Rieger

President & CEO

Canadian Organization for Rare Disorders

Durhane Wong-Rieger has served on numerous health policy advisory committees and panels and is a member of the Advisory Board for the Canadian Institutes of Health Research Institute of Genetics and the Patient Liaison Forum for the Canadian Drugs and Technologies in Health. Durhane is immediate Past-Chair of the International Alliance of Patient Organizations, and Board Member representing patient interests at DIA International Association. She has a PhD in psychology from McGill University.

 


All Sessions by Durhane Wong-Rieger

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

3:30 pm

3:30 pm

PANEL DISCUSSION: Drugs for Rare Diseases

Critical Elements for a National Strategy and Framework

With Health Canada preparing for the development and implementation of a national strategy for high-cost drugs for rare diseases, what can we learn from the COVID-19 vaccine journey? Leverage the experience of these market leaders to inform your market access strategy. Establish your game plan by:

  • Determining the types of partnerships and funding that will be key to the successful development of drugs for rare diseases
  • Analyzing the impact of recently increased government funding on the overall treatment pipeline
  • Visualizing potential safe and expeditious routes to commercialization for these medicines

Chart a course to succeed in the new market access model for rare disease therapies

Agenda: Day 2 Oct 6, 2020